Investors / Germany / CARMA Fund
CARMA Fund
Venture capital · Munich, Germany · Europe
CARMA Fund is an early-stage venture capital and transfer fund that invests in Life Science and Healthcare companies and projects. It works closely with technology transfer offices and industry partners to help translate academic research toward market entry.
Invests inHealthcare & Biotech
In its own wordslife scienceshealthcarebiotechmedtechdigital healththerapeutics
Your fit with CARMA Fund
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsCARMA Fund lists 14 checked portfolio companies on its own site and is named in 4 funding rounds. Its most frequent entry is Seed, 50% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 90% of its companies are based in Germany. It invests most often alongside High-Tech Gründerfonds, Angelini Ventures and Aschendorff NEXT.
Counts come from funding rounds that name CARMA Fund, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not CARMA Fund's whole history. Rounds on record name 4 companies; its own site lists 14. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 50% |
| Series A | 0% |
| Series B | 25% |
| Growth | 25% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 4 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 36th | 14 companies |
| Recent activity | 82th | 4 rounds in 12 months |
| Early stage | 73th | 50% of entries at pre-seed or seed |
| Evidence | 96th | 29% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 42th | 2 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| High-Tech Gründerfonds | 2 |
| Angelini Ventures | 1 |
| Aschendorff NEXT | 1 |
| Bayer G4A | 1 |
| Brandenburg Kapital | 1 |
| CRB Health Tech | 1 |
| Creative Destruction Lab | 1 |
| Eos BioInnovation | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers14100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with High-Tech Gründerfonds
Compare CARMA Fund head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Funds
as stated on its siteRecent portfolio activity
when companies last raised with CARMA Fund| Date | Company | Stage |
|---|---|---|
| 14 Oct 2026 | Series C+ | |
| 9 Sept 2026 | Seed | |
| 20 Jan 2026 | Series B | |
| 8 Jan 2026 | Seed |
Round details for CARMA Fund
Amounts, full round histories and every co-investor in CARMA Fund's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
14 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Acorai develops a non-invasive cardiac and pulmonary pressure sensing system to help healthcare professionals identify hemodynamic congestion and personalize heart failure therapy | Healthcare & Biotech | Portfolio page | ||
| Aignostics provides AI-powered tissue analysis services for life sciences, clinical, and academic applications | Healthcare & Biotech | Portfolio page | ||
| Akribion Therapeutics is developing a unique, RNA-guided, nuclease enzyme-based technology for programmable cell depletion | Healthcare & Biotech | Portfolio page | ||
| Allogenetics creates an immunological invisibility of the donor organ to prevent rejection in transplant patients | Healthcare & Biotech | Sept 2026Seed | Page + round | |
| Ceregate is developing a computer-brain interface platform for therapeutic solutions. | Healthcare & Biotech | Oct 2026Series C+ | Page + round | |
| Elkedonia is developing a neuroplastogen for antidepressant therapy | Healthcare & Biotech | Portfolio page | ||
| The company develops and provides research platforms and products for cancer classification and diagnostics | Healthcare & Biotech | Portfolio page | ||
| Exciva is developing a groundbreaking therapy that effectively and safely addresses neuropsychiatric symptoms including agitation in patients with Alzheimer’s disease dementia. | Healthcare & Biotech | Jan 2026Series B | Page + round | |
| The company develops a wearable device that analyzes signals from the abdominal area and provides recommendations for bladder emptying. | Healthcare & Biotech | Portfolio page | ||
| Kupando develops therapies to address critical unmet medical needs in cancer and infectious diseases | Healthcare & Biotech | Portfolio page | ||
| Symphera develops a system for minimally invasive surgeries that allows multiple instruments to work together and switch tools inside the body without stopping the surgery | Healthcare & Biotech | Portfolio page | ||
| TECregen develops therapies targeting thymus regeneration | Healthcare & Biotech | Jan 2026Seed | Page + round | |
| Thryve provides a secure wearable healthcare API platform for wearables and health apps | Healthcare & Biotech | Portfolio page | ||
| WMT designs precisely engineered small molecules to tackle some of the toughest remaining challenges in medicine. | Healthcare & Biotech | Portfolio page |
About this data
site last read 8 Nov 2026- Site
- carma-fund.com
- Last read
- 8 Nov 2026
- Watching since
- 7 Nov 2026
- Rounds since
- 8 Jan 2026
- Companies checked
- 14
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get CARMA Fund's profile as data
Pull CARMA Fund's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/carma-fund.com
# also
GET /v1/firms/carma-fund.com/portfolio
GET /v1/firms/carma-fund.com/coinvestors
GET /v1/firms/carma-fund.com/news